B. Riley reiterates a Buy rating on Wave Life Sciences (WVE) with a $19 price target after the company announced RestorAATion-2 data. The data were positive and demonstrated first-ever therapeutic restoration of acute phase response in homozygous for the Z mutation alpha-1antitrypsin deficiency patients, the analyst tells investors in a research note. Riley believes the disclosure de-risks both WVE-006 and Wave Life’s next RNA-editing candidate. It thinks RNA editing may be a safer alternative to gene editing, and sees a “material disconnect” between Wave Life’s current valuation and its multi-asset probability-weighted commercial opportunity. The firm remains an “aggressive” buyer of the stock.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WVE:
- Wave Life Sciences: Strong Buy Rating Backed by Promising WVE-006 Trial Results and Strategic GSK Partnership
- Wave Life Sciences price target lowered to $18 from $21 at Wells Fargo
- Why Is Wave Life Sciences Stock (WVE) Down 20% Today?
- Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!
- Optimistic Buy Rating for Wave Life Sciences Driven by Promising RNA Editing Technology and Strong Safety Profile